Royalty Pharma Plc Earnings

Royalty Pharma Plc’s revenue jumped 7.9% since last year same period to $609.29Mn in the Q3 2025. On a quarterly growth basis, Royalty Pharma Plc has generated 5.29% jump in its revenue since last 3-months.

Royalty Pharma Plc’s net profit fell -47.02% since last year same period to $288.22Mn in the Q3 2025. On a quarterly growth basis, Royalty Pharma Plc has generated 855.12% jump in its net profits since last 3-months.

Royalty Pharma Plc’s net profit margin fell -50.9% since last year same period to 47.3% in the Q3 2025. On a quarterly growth basis, Royalty Pharma Plc has generated 807.11% jump in its net profit margins since last 3-months.

Royalty Pharma Plc’s earning per share (EPS) estimates for the current quarter stand at 1.1 - a -17.29% fall from last quarter’s estimates.

Royalty Pharma Plc’s earning per share (EPS) estimates for the current year stand at 1.1.

Royalty Pharma Plc’s earning per share (EPS) fell -100% since last year same period to 0 in the Q1 2026. This indicates that the Royalty Pharma Plc has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Royalty Pharma Plc declared 0.24 dividend per share during the earnings announcement for Q1 2026.